ESOPRS KEYNOTE SPEAKERS
KEYNOTE SPEAKER 1
Lower eyelid retractors: entropion ectropion.
Hirohiko KAKIZAKI (Aichi, Japan)
Dr. Hirohiko Kakizaki, MD, PhD, is a professor at Aichi Medical University (Japan), organizing the department of Oculoplastic, Orbital & Lacrimal Surgery.
He graduated from Osaka City University Medical School in 1996.
Prof. Kakizaki completed his fellowships in Eyelid, Orbital and Lacrimal Surgeries under Mr. Raman Malhotra at the Queen Victoria Hospital (UK, 2007 & 2008) and Prof. Dinesh Selva at the University of Adelaide (Australia, 2008).
He is a past president of the Asia-Pacific & Japanese Societies of Ophthalmic Plastic & Reconstructive Surgery, editorial board members of “OPRS (Journal of American Society of OPRS)”, and “Orbit (Journal of European society of OPRS)”.
He is enthusiastic in education, in which he has trained more than 10 domestic and 40 overseas fellows.
He has published more than 300 English peer reviewed articles, more than 150 Japanese articles and 7 Japanese textbooks.
Mainly its recent anatomical confirmation of two layers of lower eyelid retractors make it possible to conceive of the role of each of these layers in the stability of the two palpebral lamellae and their involvement in the pathogenesis of the age-related lower eyelid malpositions.
KEYNOTE SPEAKER 2
Peri Orbital neurofibromas is. How to manage it ?
Naresh JOSHI (Londres, United Kingdom)
Naresh Joshi is a founder member, and ex-president of the British Ophthalmic Plastic Surgical Society (BOPSS). He heads the BOPSS and the Royal College of Ophthalmologist’s aesthetics subcommittee. He is the UK representative on ESOPRS committee.
KEYNOTE SPEAKER 3
Teprotumumab in TED.
Raymond DOUGLAS (Beverly Hills, CA, USA)
What is the main medical revolution of the last decade? Undoubtedly the emergence of targeted therapies to fight against cancer allowing dedicated and personalized medicine. In recent years, personalized medicine has also become possible in thyroid eye diseases (TED).
In 2020, the insulin growth factor receptor 1 (IGF1R) inhibitor teprotumumab gained FDA approval for the first time for the treatment of patients with TED. This approval was based on 2 randomized, controlled trials published in the prestigious New England Journal of Medicine comparing teprotumumab with a placebo. Teprotumumab demonstrated superiority over placebo in terms of clinical activity score and reduction in proptosis.
Dr Raymond DOUGLAS is a worldwide recognized oculoplastic surgeon working in Beverly Hills, California. He is also a professor at Cedars Sinai Hospital in Los Angeles where he is head of the orbital and TED programs. Dr. DOUGLAS’ lab was associated with the initial development of teprotumumab by investigating the role of IGF1R in TED. Dr DOUGLAS was respectively last and first author of the 2 clinical trials published in the New England Journal of Medicine. He treated the first patient and currently has the most experience with Teprotumumab.
Dr. DOUGLAS will tell us about his daily clinical experience with teprotumumab in TED. Most importantly, Dr. DOUGLAS will address the current challenges, questions and fears raised by the growing use of teprotumumab: Should teprotumumab be used in inactive TED? How common is hearing loss and how do you monitor it? What is the cost-benefit of teprotumumab? Will teprotumumab cause orbital decompression obsolete?
See you in Nice for the next ESOPRS congress with our special guest Dr Raymond DOUGLAS.
KEYNOTE SPEAKER 4
Lacrimal endoscopy ; myth or reality in the management of epiphora.
Karl-Heinz EMMERICH (Darmstadt, Germany)
To look inside the lacrimal was a long existing wish in the management of Epiphora.
The lacrimal system was still a myth, the diagnostic possibilities have covered the clinical examination and indirect procedures like Dacryocystographie.
Since 1995, microendoscopes with rather good quality of pictures and a maximum diameter of 1.1 mm have been presented by Storz company and Polydiagnost company. The results were first presented to the ESORPS by J. M. Piffaretti with the Storz system and by Karl-Heinz Emmerich and Hans Meyer-Rüsenberg by the Polydiagnost system. Microendoscopic procedures for recanalization of the lacrimal system like Microdrilldacryoplasty and Laserdacryoplasty have been introduced and have been developed as important tools managing epiphora.
Reality is the worldwide spreading of Dacryoendoscopy. Reality is, the experience of more than 30.000 Dacryoendoscopies by Hans Meyer-Rüsenberg an me in the last 28 years. Reality is, in most cases of PANDO microendoscopic procedures are the first step procedures and the rates of DCR in our patients could decrease from more then 30% to 10%. Reality is, DCR and Jones procedure are still keeping to be important in those cases, which are not giving the indication for micoendoscopic procedures.
So, in reality, Dacryoendoscopy has brought a lot of new insights of epiphora reasons for us and the possibility of a less traumatical, but successful treatment of Epiphora.
KEYNOTE SPEAKER mustardé lecture
Grave’s Orbitopathy a disease known for 2500 years.
Lelio BALDESCHI (BRUXELLES, Belgium
He qualified in Medicine cum laude at the University of Pisa, graduated in Ophthalmology cum laude at the University of Florence, became PhD at the University of Amsterdam and Fellow of the European Board of Ophthalmology (FEBO) (international recognition of the title of specialist in ophthalmology) in Paris. He sub-specialized in oculoplastic and orbital surgery first under the guide of Richard Collin and Geoffrey Rose at Moorfields Eye Hospital in London and then with Leo Koornneef at the Orbital Centre, University of Amsterdam.
He is Professor of Ophthalmology (“Chargé de Cours”), Director to the “Orbita and Ocular Adnexal service” and President to the PhD Council “Oculoplastic, Orbital, Lacrimal Diseases and Surgery” at the Department of Ophthalmology, Catholic University of Louvain, at the Saint Luc Academic Hospital of Brussels, member of the Examining Commission of the European Board of Ophthalmology (EBO) which grant the international recognized title of specialist in ophthalmology.
He is member of the Italian Society of Ophthalmology (SOI), European Society of Ophthalmic Plastic and Reconstructive Surgery (ESOPRS), European Association for Vision and Eye Research (EVER), has been elected among the three honorary members of the Asia Pacific Society of Ophthalmic Plastic and Reconstructive Surgery (APSOPRS), has been Secretary (2011-2014) and President (2014-2017) of the International Society of Dacryology and Dry Eye (ISD&DE), President for two terms (2010-2012 and 2013-2015) of the Italian Society of Ophthalmic Plastic Surgery (SICOP), Secretary for two terms (2014-2017 and 2018-2021) of the European Group on Graves’ Orbitopathy (EUGOGO).
Currently he is the President of the European Group on Graves’ Orbitopathy (EUGOGO), Associated Editor of Frontiers in Endocrinology and Associated Editor for orbit, oculoplastic and adult strabismus of the European Journal of Ophthalmology.
Local Organising Committee